Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This gene is a processed pseudogene related to the ribosomal protein L29 gene. Pseudogenes are DNA sequences similar to normal genes but are nonfunctional; they do not encode a functional protein and typically do not participate in canonical biological processes or disease pathways. There are multiple processed pseudogenes for ribosomal protein genes scattered throughout the genome, reflecting the evolutionary history and transcriptional redundancy of ribosome-related sequences. RPL29P13 specifically does not encode a functional protein and is not considered a therapeutic, diagnostic, or pharmacological target in biomedical research or drug development[1][3][4].\n\nRPL29 (ribosomal protein L29, not the pseudogene) is a structural constituent of the large ribosomal subunit and involved in protein synthesis in human cells, but RPL29P13 represents a nonfunctional, pseudogenized copy with no known biological or disease role[1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L29 pseudogene 13 (RPL29P13).